Treating Diseases of Aging

Treating Diseases of Aging and Treating Aging as Disease™

Immorta Bio’s technologies aim to provide your own young stem cells and your own enhanced immune cells to deal with cancers or diseases of aging the way your body dealt with them when you were young and healthy.

Conventional therapies are mediocre at best in treating diseases of aging. Immorta Bio’s approach, leveraging your younger body’s own natural mechanisms, aims at not only treating diseases of aging, but also potentially opening a door to significant healthy life extension.

Scroll for more

Aging as Disease

Aging is the ultimate risk factor for many diseases, marked by progressive deterioration of organs and tissues and an enhanced risk of disease initiation and progression including cancer, cardiovascular disease, metabolic disorders and neurodegeneration. Conventional treatments for diseases associated with aging often provide only symptomatic relief and fail to address the underlying causes of aging.

Existing stem-cell based solutions have limitations, ranging from the absence of personalized sources of "young" cells capable of replacing aging or senescent cells in various, affected organs to largely targeting only one physiological pathway or molecule. Treating aging itself, rather than just the diseases it causes, offers a comprehensive approach to improving health outcomes, increasing longevity, and extending lifespan.

Platforms

Immorta Bio is focused on two primary technology paths that have to date generated three platforms:
‍
· Cellular Rejuvenation: This technology has generated two platforms (PPCX and PMSC) of patient-specific “immortal” stem cells from their blood. These stem cells can be differentiated into young cells in unlimited quantity. Introduced into damaged or aged organ they rejuvenate surrounding cells, as well as the whole organ itself. Both platforms are applicable to multiple indications.

· Senolytic Immunotherapy: The SenoVax™ (SNVX) platform, generated from the patient’s blood and skin punch biopsy, consists of the precision targeted immune cells that enhance the body’s innate ability to self-heal. SenoVax™ is applicable to multiple cancers as well as to organ rejuvenation.

STEM CELL REVIVIFY™

Stem Cell Revivify™: rejuvenation of a damaged organ to the healthy state
using Immorta Bio Innovative Solution

PRC (Personalized Regenerative Cells):
Uniquely Derived
PPC (Personalized Progenitor Cells):
Uniquely Potent
pMSC (Personalized Mesenchymal Stem Cells):
Broadly Therapeutic
SC Revivify™ (Stem Cell Revivify):
Unique Results

Patents

1

№

63/548725

Systemic Means of Dedifferentiation

2

№

63/591063

Personalized Regenerative Cells

3

№

63/599440

Personalized Progenitor Cells

4

№

63/615296

Genetic Modification of Personalized Regenerative Cells

5

№

63/599431

Generation of Personalized Mesenchymal Stem Cells Utility

6

№

63/604864

Treatment of Liver Failure Using Personalized Progenitor Cells and Derivatives Thereof

7

№

63/604867

Treatment of Heart Failure Using Pluripotent Stem Cell Derived Cardiomyocytes and Derivatives Thereof

8

№

63/604870

Treatment of Multiple Organ Failure with Autologous Pluripotent Stem Cell Derived Therapies

9

№

63/615298

Reprogrammed Cell Modulation of Cancer Microenvironment by Tumor Homing Personalized Regenerative Cells

10

№

18/339135

Enhancement of allograft Quality by postmortem donor regeneration

11

№

63/548741

Therapeutic Use of Autologous Pluripotent Stem Cell and Differentiated Cell Exosomes

#

Patent Title

Patent No

Priority Date

17

Reduction of Senescent Cell Associated Aging and Pathology

63/673915

Jul 22, 2024

16

Enhancement of Regenerative Activity by Inactivation of Senescent Cells

63/660973

Jun 17, 2024

15

Pluripotent Stem Cell Derived Mesenchymal Stem Cells with Enhanced Immune Modulatory Activity

63/645740

May 10, 2024

14

Treatment of Liver Failure by Hepatogenic Monocytes

63/644449

May 8, 2024

13

Senescent Cell Targeting T Cell Responses by Ex Vivo Generated Antigen Presenting Cells

63/637306

Apr 22, 2024

12

Senescence Vaccine

63/560359

Mar 1, 2024

11

Systemic Means of Dedifferentiation

63/548725

Feb 1, 2024

10

Therapeutic Use of Autologous Pluripotent Stem Cell and Differentiated Cell Exosomes

63/548741

Feb 1, 2024

9

Genetic Modification of Personalized Regenerative Cells

63/615296

Dec 28, 2023

8

Reprogrammed Cell Modulation of Cancer Microenvironment by Tumor Homing Personalized Regenerative Cells

63/615298

Dec 28, 2023

7

Treatment of Liver Failure Using Personalized Progenitor Cells and Derivatives Thereof

63/604864

Nov 30, 2023

6

Treatment of Heart Failure Using Pluripotent Stem Cell Derived Cardiomyocytes and Derivatives Thereof

63/604867

Nov 30, 2023

5

Treatment of Multiple Organ Failure with Autologous Pluripotent Stem Cell Derived Therapies

63/604870

Nov 30, 2023

4

Personalized Progenitor Cells

63/599440

Nov 15, 2023

3

Generation of Personalized Mesenchymal Stem Cells

63/599431

Nov 15, 2023

2

Personalized Regenerative Cells

63/591063

Oct 17, 2023

1

Enhancement of allograft Quality by postmortem donor regeneration

18/339135

Jun 21, 2022

Number

Patent name

Registration number

1

Personalized Regenerative Cells

63/591063

2

Genetic Modification ofPersonalized Regenerative Cells

63/615296

3

Personalized Progenitor Cells

63/599440

4

Generation of Personalized Mesenchymal Stem Cells Utility

63/599431

5

Treatment of Liver Failure Using Personalized Progenitor Cells andDerivatives Thereof

63/604864

6

Treatment of Heart Failure Using Pluripotent Stem Cell DerivedCardiomyocytes and Derivatives Thereof

63/604867

7

Treatment of Multiple Organ Failure with Autologous Pluripotent StemCell Derived Therapies

63/604870

8

Reprogrammed Cell Modulation of Cancer Microenvironment by Tumor HomingPersonalized Regenerative Cells

63/615298

9

Enhancement of allograft Quality by postmortem donor regeneration

18/339135

Collaboration Opportunities

At Immorta Bio, we maintain exclusive marketing rights for our innovative therapeutic programs and are currently raising funds to advance clinical trials, upgrade lab facilities, and support ongoing research and development for our rejuvenation programs. We seek strategic partnerships to maximize their commercial potential, typically after reaching the proof-of-efficacy stage. Contact us to explore collaboration opportunities.

Contact Us

Management Team

Boris Reznik, Ph.D.

Chairman and CEO

More

Thomas Ichim, Ph.D.

President and CSO

More

Vladyslav Bykoriz, MD, Ph.D.

Chief Medical Officer

More

Yuri Kaplun, Ph.D.

Chief Information Officer

More

News and Resources

December 18, 2024

Immorta Bio Advances Lung Cancer Immunotherapy with Peer-Reviewed Animal Data on Senolytic Vaccine

Nature Publication Supports Senolytic Approach for Cancer Treatment

Immorta CSO Featured in BioFuture 2024 Longevity Panel

Careers

Immorta Bio embodies a team-centric ethos, comprising highly devoted and skilled individuals. Our collaborative teams operate synergistically within a dynamic, enjoyable, and creatively fulfilling environment. Upholding principles of high integrity, mutual respect, teamwork, open-mindedness, and scientific excellence, we prioritize recruiting, developing, and retaining individuals possessing the determination and expertise essential for success.

We provide compelling career opportunities for individuals passionate about life extension and dedicated to supporting advancements in the biotechnology field.

View job openings

Join our newsletter to stay up to date on features and releases

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

By subscribing, you are acknowledging your consent to receive Immorta Bio newsletters

19505 Biscayne Blvd, Ste 2350 Aventura, Florida 33180

305 632-2939

info@immortabio.com

Privacy Policy